Fundraising Fox
/Companies
Sign in

Trio Pharmaceuticals

San Diego, US · Founded 2018 · Delaware corporation · 3 known investors

Find your way into Trio Pharmaceuticals

Sign up to find every way you can get introduced to Trio Pharmaceuticals

  • Your email: who you already know at Trio Pharmaceuticals, and who your contacts know
  • 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Trio Pharmaceuticals team
  • Your LinkedIn: the connections who can make the intro for you

We rank every route by how warm it is, so you raise on warm intros instead of cold emails.

Sign up with GoogleAlready have an account? Log in

Trio Pharmaceuticals develops dual-targeting antibody drugs to treat cancer, using its TIE-ADC and TRAILBody platforms to kill cancer cells and overcome tumor immunosuppression while reducing treatment-related toxicity. Its pipeline targets blood cancers (AML/MDS), ovarian and endometrial cancers, and triple-negative breast and non-small cell lung cancers.

BiotechHealthtech

Founders & leadership

Trio Pharmaceuticals was founded in 2018 by H. Kim Lyerly.

HKH. Kim Lyerly
H. Kim LyerlyCMO & Founder
RL
Reiner LausNamed on SEC filing
SB
Shivarupam BhowmikNamed on SEC filing
JF
Jeffrey FriedmanNamed on SEC filing

Investors · 3

Also in the syndicate · 2

Friedman BioVenturesleadNewsight Tech Angels Inc.

Reported raises · per SEC filings

Form D private placements

$1.9M disclosed across 1 round · 2022

▶$1.9MraisedDec 2022 · 9 investors · Other
Rule 506(b)
Officers, directors & promoters on the filing
  • Reiner LausExecutive Officer, Director
  • Shivarupam BhowmikExecutive Officer, Director
  • Jeffrey FriedmanDirector
Offering amount
$2.4M
Amount sold
$1.9M
First sale
Nov 2022
Incorporated
Corporation, Delaware, 2018
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Related companies · 3

Eli LillyEli Lilly discovers, develops, manufactures, and markets human pharmaceutical products across cardiometabolic, oncology, immunology, and neuroscience therapeutic areas, selling to healthcare providers and patients in approximately 90 countries through wholesalers, direct sales representatives, and digital platforms.
SoluSolu Therapeutics is a clinical-stage biotech developing a class of antibody therapeutics that link bifunctional small molecules to proprietary effector antibodies (its CyTAC and TicTAC platforms) to reach cell surface targets like GPCRs and ion channels. Its pipeline targets oncology, immunology and inflammation, and pain, with a lead program in Phase 1 trials for chronic myelomonocytic leukemia.
BioworldBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.

Companies working in the same space as Trio Pharmaceuticals.

Frequently asked questions

What does Trio Pharmaceuticals do?
Trio Pharmaceuticals develops dual-targeting antibody drugs to treat cancer, using its TIE-ADC and TRAILBody platforms to kill cancer cells and overcome tumor immunosuppression while reducing treatment-related toxicity. Its pipeline targets blood cancers (AML/MDS), ovarian and endometrial cancers, and triple-negative breast and non-small cell lung cancers.
Who founded Trio Pharmaceuticals?
Trio Pharmaceuticals was founded by H. Kim Lyerly in 2018.
Who are Trio Pharmaceuticals's investors?
Trio Pharmaceuticals's investors include NuFund Venture Group.
How much funding has Trio Pharmaceuticals raised?
Trio Pharmaceuticals has disclosed $1.9M raised across 1 round.
Where is Trio Pharmaceuticals headquartered?
Trio Pharmaceuticals is headquartered in San Diego, US.